Notably, BRAF mutations demonstrated a significantly higher frequency in patients with lung cancer with IPF, accounting for 6 of 35 cases (17.1%) [44], which is much higher than the known prevalence of 2–4% in the general lung cancer population [45,46]. The gene discussed is BRAF; the disease is lung cancer.